<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article293</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PRoFESS" style="display:block; margin-bottom:10px;">PRoFESS Original</a></li>
<h2><strong>PRoFESS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Comparison of Aspirin plus Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke".<br/>
The New England Journal of Medicine. <br/>
PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does the combination of aspirin plus extended-release dipyridamole (ASA–ERDP) reduce the risk of recurrent stroke compared to clopidogrel alone in patients with a recent ischemic stroke?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Aspirin plus extended-release dipyridamole (ASA–ERDP) is not inferior to clopidogrel in reducing the risk of recurrent stroke, but does not meet predefined criteria for noninferiority. There is no evidence that either treatment is superior to the other for preventing recurrent stroke.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines do not specifically recommend one antiplatelet therapy over the other for secondary stroke prevention.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, parallel group, randomized, controlled 2-by-2 factorial trial comparing ASA–ERDP and clopidogrel.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Recent ischemic stroke<br/>
- Age ≥55 years or older (later amended to ≥50 years with additional risk factors)<br/>
- Clinically and neurologically stable prior to randomization<br/>
<br/>
Exclusion Criteria:<br/>
- Contraindications to the antiplatelet agents<br/>
- Unsuitability for randomization based on clinical judgment<br/>
<br/>
Baseline Characteristics: Age 66.1 years, 36.0% female, majority had a history of hypertension, 28.2% had diabetes.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomly assigned to receive either ASA–ERDP or clopidogrel.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome:<br/>
- Recurrence of stroke<br/>
<br/>
Secondary Outcome:<br/>
- Composite of stroke, myocardial infarction, or death from vascular causes<br/>
<br/>
Tertiary Outcomes:<br/>
- Recurrence of stroke or major hemorrhagic event<br/>
- New or worsening congestive heart failure<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The trial's noninferiority margin was conservative, leading to the inability to claim noninferiority despite similar effectiveness in the two treatment groups.<br/>
- The trial was underpowered for noninferiority if the actual effectiveness was equivalent between the treatments.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by Boehringer Ingelheim, manufacturer of Aggrenox (ASA-ERDP) and Micardis (telmisartan). Additional support in selected countries by Bayer Schering Pharma and GlaxoSmithKline for the telmisartan comparison.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
ClinicalTrials.gov: NCT00153062.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
